With the big American Society of Clinical Oncology meeting coming up in two weeks, anticipation about the coming onslaught of data is mounting. Last night, ASCO released some key abstracts for studies to be presented at the meeting, offering an aperitif to oncology-drug followers. Here is a sampling of news, some from our sister publication FierceBiotech.
Onyx Pharmaceuticals has climbed the list of deal-hungry biopharma companies. CEO Tony Coles has built an enviable war chest after a stellar year, and he wants to buy or advance new drugs that could take the company to the next level of the pharma industry.
Analysts at GlobalData took a quarterly snapshot of the R&D expenses for a big batch of mid-cap biotechs and concluded that rising research costs were eroding corporate profitability. And they pinned the blame squarely on the pricey hunt for new cancer drugs.
Fresh from back-to-back regulatory wins for Stivarga and Kyprolis, fast-growing Onyx Pharmaceuticals is adding a new building with more than 100,000 square feet of space to its South San Francisco campus.
Three months after landing FDA fast-track review status for regorafenib , Bayer 's top cancer prospect, today the agency delivered an approval as a treatment for colorectal cancer . The approval comes after a tumultuous lawsuit filed in 2009 by Onyx Pharmaceuticals ( $ONXX ), claiming the compound can be distinguished from Nexavar by only a single atom. Here's a look back at regorafenib's history.
Teva Pharmaceutical Industries ($TEVA) is the biggest fish in today's earnings pond. The generics giant--which now has a sizable footprint in branded drugs, thanks to its Cephalon buyout--met expectations on profits and sales, but didn't excite anyone in the process. Meanwhile, a gaggle of smaller pharmas let their second-quarter results fly.
Onyx Pharmaceuticals has staffed up to launch its newly approved Kyprolis drug for multiple myeloma. The company hired a dedicated marketing team of about 100, Xconomy reports, comprising sales reps, oncology nurses and reimbursement specialists.
Nexavar plus Tarceva did not equate to improved survival for liver cancer patients in a new trial. But that doesn't mean Nexavar is losing its edge.
Onyx nailed an FDA approval today for the multiple myeloma drug Kyprolis (carfilzomib), overcoming the naysayers who were skeptical that the agency would hand out an accelerated OK for a new drug on just mid-stage data drawn from a single-arm study.
Bristol-Myers Squibb swung for the fences and whiffed, and the company's major miss provides a victory to Onyx Pharmaceuticals, the white-hot provider of Nexavar.